<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03912363</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0502</org_study_id>
    <nct_id>NCT03912363</nct_id>
  </id_info>
  <brief_title>Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids</brief_title>
  <official_title>Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids: Randomized Controlled Trial (RCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geisinger Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geisinger Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether rotating intravenous (IV) fluid is better than receiving
      insulin to control a baby's blood sugar after delivery in laboring women with diabetes. A
      computer will choose the method of controlling the participant's blood sugar while they are
      in labor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes complicates 6-9% of all pregnancies. Of those pregnancies, 90% of pregnant diabetics
      have gestational diabetes mellitus (GDM), while the remainder of patients have pre-existing
      diabetes mellitus (DM). Maternal hyperglycemia has a negative impact on maternal and
      fetal/neonatal health. Adverse neonatal outcomes include birth injuries, respiratory
      distress, and metabolic derangements such as hypoglycemia. The incidence of neonatal
      hypoglycemia is higher in pregnancies complicated by pre-existing DM (24-48%) when compared
      to patients with GDM (16-19%).

      Neonatal hypoglycemia causes immediate and long-term morbidity. Treatment of hypoglycemia may
      require admission to the Neonatal Intensive Care Unit (NICU). The severity and duration of
      neonatal hypoglycemia raises concern for permanent neurologic damage to the neonate. Even
      transient episodes of neonatal hypoglycemia have been associated with neurodevelopmental
      impairment. It is imperative that measures be taken in diabetic mothers (both pre-existing
      and gestational) to minimize the risk of neonatal hypoglycemia. While antepartum maternal
      glucose control remains an important factor in preventing neonatal complications, prevention
      of maternal hyperglycemia during the intrapartum period has been shown to reduce the risk of
      neonatal hypoglycemia.

      Therapies utilized for maternal intrapartum glycemic control across academic centers in the
      United States include the use of insulin and rotation of intravenous (IV) fluids. Although
      used in clinical practice for intrapartum glycemic control, the impact of rotating IV fluids
      on neonatal blood glucose is unknown. The potential for using rotating IV fluids to control
      intrapartum blood glucose has several advantages over using insulin for optimization of blood
      glucose. There is minimal risk of maternal hypoglycemia using IV fluids when compared to
      insulin therapy. There is also less risk of medication error. IV fluids are easily
      administered as they do not require separate peripheral access and are easily accessible on a
      Labor and Delivery (L&amp;D) unit.

      The investigators propose a randomized controlled trial (RCT) to assess the effect of
      maternal intrapartum glycemic control with rotating IV fluids compared to insulin infusion on
      neonatal blood glucose levels within two hours of birth. The investigators hypothesize
      neonates born to mothers managed by rotating fluids will have higher neonatal blood glucose
      levels (closer to normal range) within two hours of birth compared to neonates born to
      mothers managed by insulin infusion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neonatal blood glucose value</measure>
    <time_frame>Within 2 hours of life</time_frame>
    <description>Neonatal blood glucose value from birth to 2 hours of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean neonatal blood glucose value</measure>
    <time_frame>First 24 hours of life</time_frame>
    <description>Average of neonatal blood glucose values from birth to 24 hours of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of maternal hypoglycemia</measure>
    <time_frame>During labor (average time 24 hours)</time_frame>
    <description>Blood glucose value &lt; 50 mg/dL without symptoms OR Blood glucose value &lt; 70 mg/dL with symptoms such as perspiration, palpitations, tremor, weakness, anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean intrapartum maternal blood glucose value</measure>
    <time_frame>During labor (average time 24 hours)</time_frame>
    <description>Average of maternal blood glucose values during labor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal blood glucose value before delivery</measure>
    <time_frame>Within one hour of delivery</time_frame>
    <description>Blood glucose value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of composite neonatal outcome</measure>
    <time_frame>First 24 hours of life until discharge (average time 21 days)</time_frame>
    <description>Neonatal hypoglycemia, NICU admission, neonatal hyperbilirubinemia, and neonatal respiratory distress syndrome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Type II Diabetes Mellitus</condition>
  <condition>Gestational Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Rotating fluids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rotating fluids protocol will be initiated at the time of admission to Labor and Delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin infusion protocol will be initiated at the time of admission to Labor and Delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rotating fluids protocol</intervention_name>
    <description>IV fluids at a rate of 100-150 ml/hr will be administered:
For blood glucose &lt; 100 mg/dL or less: IV fluids with 5% dextrose
For blood glucose between 101-140 mg/dL: IV fluids without 5% dextrose
For blood glucose &gt; 140 mg/dL on two consecutive occasions: insulin infusion protocol (Study arm 2)</description>
    <arm_group_label>Rotating fluids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Insulin infusion protocol</intervention_name>
    <description>Regular insulin at 1 unit/ml AND IV fluids at a rate of 100-150 ml/hr will be administered:
For blood glucose &lt; 80 mg/dL: No insulin AND IV fluids with 5% dextrose
For blood glucose 80-100 mg/dL: Insulin at 0.5 U/hr AND IV fluids with 5% dextrose
For blood glucose 101-140 mg/dL: Insulin at 1.0 U/hr AND IV fluids with 5% dextrose
For blood glucose 141-180 mg/dL: Insulin at 1.5 U/hr AND IV fluids with 5% dextrose
For blood glucose 181-220 mg/dL: Insulin at 2.0 U/hr AND IV fluid without dextrose
For blood glucose &gt; 220 mg/dL: Insulin at 2.5 U/hr AND IV fluids without dextrose</description>
    <arm_group_label>Insulin infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women with Type II diabetes mellitus or GDM controlled with insulin and/or
             hypoglycemic medication (GDMA2)

          -  Singleton pregnancies

          -  Gestational age between 37 0/7 weeks and 40 0/7 weeks

          -  Planned delivery at a Geisinger Medical Center (GMC) or Geisinger Wyoming Valley (GWV)

          -  English or Spanish speaking

          -  Anticipated delivery at ≥ 4 hours from randomization (e.g., cervical dilation at ≤ 7
             cm at time of randomization)

        Exclusion Criteria:

          -  Women with Type 1 diabetes mellitus or use of insulin pump

          -  Evidence of diabetic ketoacidosis at time of admission for delivery

          -  Multifetal gestation

          -  Gestational age &lt; 37 0/7 weeks or &gt; 40 0/7 weeks

          -  Non-English or Non-Spanish speaking

          -  Anticipated delivery &lt; 4 hours from randomization (e.g., cervical dilation &gt; 7 cm at
             time of randomization, first cesarean delivery of the day)

          -  Oral corticosteroid use within 48 hours of planned delivery

          -  Antenatal corticosteroid use within 7 days of admission for delivery

          -  Delivery planned outside of GMC or GWV

          -  Fetal demise

          -  Prenatal diagnosis of lethal fetal anomaly

          -  Active infection or immunocompromised state (e.g., HIV/AIDS, active malignancy, use of
             immunosuppressant medication) at time of admission for delivery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Paglia, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geisinger Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael J Paglia, MD, PhD</last_name>
    <phone>570-714-1099</phone>
    <email>mjpaglia@geisinger.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kajal Angras, DO</last_name>
    <phone>570-271-8160</phone>
    <email>kangras@geisinger.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Geisinger</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J Paglia, MD, PhD</last_name>
      <phone>570-714-1099</phone>
      <email>mjpaglia@geisinger.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kajal Angras, DO</last_name>
      <phone>570-271-8160</phone>
      <email>kangras@geisinger.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael J Paglia, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kajal Angras, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Wyoming Valley</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J Paglia, MD, PhD</last_name>
      <phone>570-714-1099</phone>
      <email>mjpaglia@geisinger.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kajal Angras, DO</last_name>
      <phone>570-271-8160</phone>
      <email>kangras@geisinger.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael J Paglia, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kajal Angras, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>DeSisto CL, Kim SY, Sharma AJ. Prevalence estimates of gestational diabetes mellitus in the United States, Pregnancy Risk Assessment Monitoring System (PRAMS), 2007-2010. Prev Chronic Dis. 2014 Jun 19;11:E104. doi: 10.5888/pcd11.130415.</citation>
    <PMID>24945238</PMID>
  </reference>
  <reference>
    <citation>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus. Obstet Gynecol. 2018 Dec;132(6):e228-e248. doi: 10.1097/AOG.0000000000002960.</citation>
    <PMID>30461693</PMID>
  </reference>
  <reference>
    <citation>HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008 May 8;358(19):1991-2002. doi: 10.1056/NEJMoa0707943.</citation>
    <PMID>18463375</PMID>
  </reference>
  <reference>
    <citation>Rosenberg VA, Eglinton GS, Rauch ER, Skupski DW. Intrapartum maternal glycemic control in women with insulin requiring diabetes: a randomized clinical trial of rotating fluids versus insulin drip. Am J Obstet Gynecol. 2006 Oct;195(4):1095-9. Epub 2006 Aug 8.</citation>
    <PMID>16893507</PMID>
  </reference>
  <reference>
    <citation>Golde SH, Good-Anderson B, Montoro M, Artal R. Insulin requirements during labor: a reappraisal. Am J Obstet Gynecol. 1982 Nov 1;144(5):556-9.</citation>
    <PMID>6753588</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intrapartum</keyword>
  <keyword>glycemic control</keyword>
  <keyword>diabetes</keyword>
  <keyword>insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

